InnovAge Holding Corp.
4.8200-0.26 (-5.12%)
Oct 29, 4:00:01 PM EDT · NasdaqGS · INNV · USD
Key Stats
Market Cap
653.98MP/E (TTM)
-Basic EPS (TTM)
-0.22Dividend Yield
0%Recent Filings
8-K
8-K
InnovAge's FY25 revenue up 11.8%
InnovAge Holding Corp. reported fiscal 2025 results on September 9, 2025, with total revenues climbing 11.8% to $853.7 million, driven by a census expansion to 7,740 participants, while net loss widened to $35.3 million amid higher litigation and impairment costs. Adjusted EBITDA surged to $34.5 million, boosting the margin to 4.0% from 2.2%, reflecting disciplined growth and clinical execution. Momentum builds. For fiscal 2026, the company guides revenues to $900-$950 million and Adjusted EBITDA to $56-$65 million, though litigation risks persist.
10-K
FY2025 results
InnovAge Holding Corp. filed its 10-K for the fiscal year ended June 30, 2025, but the provided filing lacks financial statements, MD&A, or quarterly results, so specific topline, profitability, or momentum metrics are not disclosed. The document highlights equity incentive grants under the TCO Group Holdings, L.P. Equity Incentive Plan, awarding Class B Units—profits interests with a $3.68 hurdle—to executives like Patrick Blair (3,867,318 units), Benjamin C. Adams (1,841,323 units), and Nicole D'Amato (366,602 units) on September 5, 2025. Vesting splits one-third time-based over three years and two-thirds performance-based on Apax Investor's MOIC targets from 1.04x to 1.68x. No capital allocation or liquidity details appear. Annual guidance remains undisclosed. Regulatory changes in healthcare could disrupt quarterly operations.
8-K
InnovAge refinances debt facilities
InnovAge Holding Corp. refinanced its existing credit facilities on August 8, 2025, replacing the prior term loan with a $50.7 million Term Facility and renewing the $100.0 million Revolver, extending maturities to August 8, 2028. This move provides two extra years of runway, easing near-term debt pressures while keeping interest tied to SOFR or the base rate plus a leverage-based margin. Lenders waived breakage costs, signaling smooth execution.
10-Q
Q3 FY2025 results
InnovAge's Q3 FY2025 capitation revenue climbed 13.0% y/y to $217.8M, fueled by 10.7% higher member months and 2.1% rate gains, while external provider costs rose 7.9% y/y yet eased 2.5% per participant on lower utilization and in-house pharmacy shifts. Operating loss widened to $10.2M from $5.8M y/y, pressured by 17.6% higher care costs from wage hikes and headcount, plus a $10.7M stockholder settlement accrual; net loss hit $11.1M versus $6.2M y/y, with the gap tied to that one-time hit and taxes. Cash swelled to $60.5M, bolstered by $23.9M operating cash flow, while free cash flow (derived) stood at $17.5M after $6.4M capex; debt dipped to $63.1M with $94.8M revolver availability. The TRHC pharmacy tuck-in closed January 2025 for $4.8M cash, adding $2.1M goodwill to sharpen cost controls. Regulatory probes linger as a key risk.
IPO
Website
Employees
Sector
Industry
ADUS
Addus HomeCare Corporation
122.75+2.22
AGL
agilon health, inc.
0.86-0.05
EHAB
Enhabit, Inc.
8.50-0.03
IMTH
Innovative MedTech Inc.
0.14-0.00
MD
Pediatrix Medical Group, Inc.
17.87+0.03
NHC
National HealthCare Corporation
120.85-1.15
PACS
PACS Group, Inc.
12.44+0.02
PIII
P3 Health Partners Inc.
8.66-0.22
PNTG
The Pennant Group, Inc.
25.03-0.86
SNDA
Sonida Senior Living, Inc.
25.73-0.44